Ann: European RAT Clinical Trial Halted to Refocus Initiatives, page-22

That’s a quick turnaround from the recent quarterly:

2. Submission EU Common List Registration - The clinical trial in Europe is ongoing. AnteoTech remains on track for the European Common List registration submission in Q2 FY2023.

Hopefully nobody invested after reading that the EU common List Application was to be submitted imminently.

The question is, was this the decision of an incoming CEO making quick decisions to save the company, or again was this a car crash in the making, being that the outlier information has been kept quiet.

At least someone made a quick decision for once.